Departament de Bioquímica i Biomedicina Molecular, Facultat de Biologia, Universitat de Barcelona, Barcelona, Spain.
Unitat d'Hormones, Servei de Bioquímica, Hospital Universitari de la Vall d'Hebron, Barcelona, Spain.
Int J Obes (Lond). 2017 Sep;41(9):1388-1393. doi: 10.1038/ijo.2017.115. Epub 2017 May 10.
The notion that hepatic expression of genes involved in lipid metabolism is altered in obese patients is relatively new and its relationship with hepatic steatosis and cardiometabolic alterations remains unclear.
We assessed the impact of Roux-en-Y gastric bypass surgery (RYGB) on the expression profile of genes related to metabolic syndrome in liver biopsies from morbidly obese individuals using a custom-made, focused cDNA microarray, and assessed the relationship between the expression profile and hepatic steatosis regression.
Plasma and liver samples were obtained from patients at baseline and 12 months after surgery. Samples were assayed for chemical and gene expression analyses, as appropriate. Gene expression profiles were assessed using custom-made, focused TaqMan low-density array cards.
RYGB-induced weight loss produced a favorable reduction in fat deposits, insulin resistance (estimated by homeostasis model assessment of insulin resistance (HOMA-IR)), and plasma and hepatic lipid levels. Compared with the baseline values, the gene expression levels of key targets of lipid metabolism were significantly altered: CD36 was significantly downregulated (-40%; P=0.001), whereas APOB (+27%; P=0.032) and SCARB1 (+37%; P=0.040) were upregulated in response to surgery-induced weight reduction. We also observed a favorable reduction in the expression of the PAI1 gene (-80%; P=0.007) and a significant increase in the expression of the PPARA (+60%; P=0.014) and PPARGC1 genes (+36%; P=0.015). Notably, the relative fold decrease in the expression of the CD36 gene was directly associated with a concomitant reduction in the cholesterol (Spearman's r=0.92; P=0.001) and phospholipid (Spearman's r=0.76; P=0.04) contents in this tissue.
For the first time, RYGB-induced weight loss was shown to promote a favorable downregulation of CD36 expression, which was proportional to a favorable reduction in the hepatic cholesterol and phospholipid contents in our morbidly obese subjects following surgery.
涉及脂质代谢的基因在肥胖患者肝脏中的表达发生改变的观点相对较新,其与肝脂肪变性和心脏代谢改变的关系尚不清楚。
我们使用定制的、有针对性的 cDNA 微阵列评估肥胖个体的肝活检中与代谢综合征相关的基因表达谱在 Roux-en-Y 胃旁路手术 (RYGB) 后的变化,并评估基因表达谱与肝脂肪变性消退之间的关系。
在手术前和手术后 12 个月从患者中获取血浆和肝脏样本。适当的样本进行化学和基因表达分析。使用定制的、有针对性的 TaqMan 低密度阵列卡评估基因表达谱。
RYGB 诱导的体重减轻导致脂肪沉积、胰岛素抵抗(通过稳态模型评估的胰岛素抵抗(HOMA-IR)来估计)以及血浆和肝脂质水平的有利降低。与基线值相比,脂质代谢关键靶标基因的表达水平显著改变:CD36 显著下调(-40%;P=0.001),而 APOB(+27%;P=0.032)和 SCARB1(+37%;P=0.040)则因手术引起的体重减轻而上调。我们还观察到 PAI1 基因的表达显著降低(-80%;P=0.007),PPARA(+60%;P=0.014)和 PPARGC1 基因(+36%;P=0.015)的表达显著增加。值得注意的是,CD36 基因表达的相对折叠减少与该组织中胆固醇(Spearman's r=0.92;P=0.001)和磷脂(Spearman's r=0.76;P=0.04)含量的相应降低直接相关。
首次表明,RYGB 诱导的体重减轻可促进 CD36 表达的有利下调,这与我们肥胖患者手术后肝胆固醇和磷脂含量的有利降低成正比。